Acquisition marks a significant step in Apotex's growth strategy, advancing its position as a preferred Health Partner of Choice in the Americas.

此次收购标志着Apotex增长战略迈出了重要一步，提升了其作为美洲首选健康合作伙伴的地位。

TORONTO, June 3, 2024 /PRNewswire/ - Apotex Inc. ('Apotex' or the 'Company') today announced the successful completion of its acquisition of Searchlight Pharma Inc. ('Searchlight'), a leading Canadian specialty innovative branded pharmaceutical company. This acquisition accelerates the company's growth within the specialty innovative branded pharmaceutical market, reaffirming Apotex's commitment to delivering high-quality, innovative solutions to patients and consumers around the world.

多伦多，2024年6月3日/PRNewswire/-Apotex Inc.（“Apotex”或“公司”）今天宣布成功完成对加拿大领先的专业创新品牌制药公司Searchlight Pharma Inc.（“Searchlight”）的收购。此次收购加速了公司在专业创新品牌制药市场的增长，重申了Apotex致力于为世界各地的患者和消费者提供高质量的创新解决方案。

Searchlight is now operating as the Specialty Pharma Division of Apotex and will be led by Mark Nawacki, President of Searchlight..

探照灯目前是Apotex的专业制药部门，将由探照灯总裁马克·纳瓦基（Mark Nawacki）领导。。

Apotex's expertise in generic and biosimilar pharmaceuticals, combined with Searchlight's strong specialty and innovative branded product portfolio, enhances the company's position as a pharmaceutical powerhouse in Canada. 'This strategic move aligns with our vision to better serve patients and consumers along their health journey by adding a diverse portfolio of value add and specialty innovative branded products,' stated Allan Oberman, President and CEO of Apotex.

Apotex在仿制药和生物仿制药方面的专业知识，加上探照灯强大的专业性和创新的品牌产品组合，增强了该公司作为加拿大制药巨头的地位。”Apotex总裁兼首席执行官艾伦·奥伯曼（AllanOberman）表示，这一战略举措符合我们的愿景，即通过增加增值和专业创新品牌产品的多样化组合，更好地为患者和消费者的健康之旅服务。

'We are pleased to welcome Searchlight to the Apotex team and look forward to leveraging the synergies between our teams to accelerate our continued growth.'.

“我们很高兴欢迎探照灯加入Apotex团队，并期待利用我们团队之间的协同作用来加速我们的持续增长。”。

On May 24, 2024, Apotex entered its 50th year of business, marking a significant achievement rooted in improving patient access to affordable medicines. For five decades, Apotex has consistently expanded access to complex health products and remains committed to creating new products that address unmet medical needs, facilitating improved global access to essential pharmaceuticals.

2024年5月24日，Apotex进入了其业务的第50个年头，这标志着一项重大成就，其根源在于改善患者获得负担得起的药物的机会。五十年来，Apotex一直在扩大对复杂健康产品的获取，并继续致力于创造新产品，以满足未满足的医疗需求，促进全球获得基本药物的机会。

'Building on our 50-year legacy, this acquisition supports our renewed strategic focus to diversify beyond traditional generic pharmaceuticals, positioning Apotex as a Health Partner of Choice in the Americas,' added Mr. Oberman..

奥伯曼补充说：“在我们50年历史的基础上，此次收购支持了我们重新确立的战略重点，使我们的战略重点不再局限于传统仿制药，将Apotex定位为美洲首选的健康合作伙伴。”。。

About Apotex Inc.

关于Apotex Inc。

Apotex is a Canadian-based global health company with a portfolio of generic, biosimilar, and innovative branded pharmaceutical products that meet a broad set of patient and consumer needs. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico and India, and an extensive international distribution network, Apotex has led the Canadian generic pharmaceutical market for decades.

Apotex是一家总部位于加拿大的全球健康公司，拥有仿制药、生物仿制药和创新品牌药品的组合，可满足广泛的患者和消费者需求。Apotex总部位于多伦多，在美国、墨西哥和印度等地设有全球区域办事处，并拥有广泛的国际分销网络，几十年来一直领导着加拿大仿制药市场。

As the largest Canadian-based pharmaceutical company and a health partner of choice for pharmaceutical licensing and product acquisitions, Apotex delivers high-quality, affordable and complex medicines around the world. Apotex is a portfolio company of SK Capital Partners. Learn more about Apotex's commitment over the last 50 years to improve everyday access to innovative medicines and health products at www.apotex.com..

作为加拿大最大的制药公司和制药许可和产品收购的首选健康合作伙伴，Apotex在世界各地提供高质量，价格合理和复杂的药物。Apotex是SK Capital Partners的投资组合公司。请访问www.Apotex.com，了解更多有关Apotex在过去50年中致力于改善创新药物和保健产品日常使用的信息。。

SOURCE Apotex Inc.

资料来源：Apotex公司。